I read the article by Gordon et al1 with great interest. I agree that further studies are necessary to assess the safety and efficacy of combinations of chelating agents in humans. In a rat model, Flora et al2 found that the combined regimen of calcium disodium EDTA and meso-2,3 dimercaptosuccinic acid elicited a greater urinary lead elimination and a lower blood lead level than either agent alone. However, the combined regimen was associated with an elevation of the serum transaminase and creatinine levels. Did Gordon et al monitor renal and hepatic functions during the treatment of their patient? If so, were abnormalities noted?
Campbell JR. Treatment of Acute Lead Encephalopathy. Arch Pediatr Adolesc Med. 1999;153(11):1202. doi:10.1001/archpedi.153.11.1202
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: